

# Introducing Evaluate CDMO Intelligence for Financial Services

**Simplify the complex pharma CDMO market with game-changing insights at your fingertips.**



The pharma CDMO market is on an upward trajectory, set to grow 7.29% each year out to 2028. As biopharma firms increasingly collaborate with CDMOs, the landscape is ripe with opportunity. Are you primed to tap into this expanding market?

**Do you have the specialist CDMO intelligence you need to support your investment decisions, size market opportunity, and position yourself for success in an ever-changing industry?**

## **This is where Evaluate CDMO Intelligence steps in**

Use our time-saving intelligence solution to strategically select, profile, and compare CDMOs, accelerate your due diligence, enhance your M&A advisory services, and stay ahead of the competition.

### **HOW WE HELP:**



Grasp the diverse capabilities of CDMOs, understanding their unique strengths.



Quickly familiarise yourself with various manufacturing segments and markets.



Analyse future demand, market size, and the strengths of established players.



Feel confident in performing due diligence and selecting the most advantageous angles and expertise for your M&A advisory services.



Leverage best-in-class intelligence to bypass challenging desk research, using only trusted sources.

### **ONLY EVALUATE EQUIPS YOU TO:**



Project revenue with leading drug sales forecasting.



Predict regulatory success through machine learning.



Assess demand with one-of-a-kind drug volume forecasts.

**Evaluate**  
a norstella company

**Accelerate your business growth and seize new opportunities.**

Contact us to discover how Evaluate CDMO Intelligence can unlock deep insights and save you time.

[info@evaluate.com](mailto:info@evaluate.com) | [www.evaluate.com](http://www.evaluate.com)

Evaluate HQ: +44-(0)20-7377-0800 | Evaluate Americas: +1-617-573-9450 | Evaluate APAC: +81-(0)80-1164-4754